Paclitaxel, Carboplatin og Bevacizumab eller Paclitaxel, Carboplatin og Temsirolimus eller Ixabepilone, Carboplatin og Bevacizumab til behandling af patienter med trin III, trin IV eller tilbagevendende endometriecancer
Et tre-arms randomiseret fase II-studie af Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) og Ixabepilone (NSC #710428)/Carboplatin/Bevacizumbehandling S som IVA-behandling, behandling med behandling, behandling med behandling, behandling, behandling med behandling, Stadie IVB eller tilbagevendende endometriecancer
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Endometrie clear cell adenocarcinoma
- Endometrial serøst adenokarcinom
- Endometrial Adenocarcinom
- Endometrial Adenosquamous Carcinom
- Gentagne maligne livmoderkorpus neoplasma
- Trin IIIa Uterin Corpus Carcinoma eller Carcinosarcoma af AJCC V7 -trin
- Trin IIIB Livterin Corpus Carcinoma eller Carcinosarcoma af AJCC V7 Stage
- Trin IIIC livmoderkorpuscarcinom eller carcinosarkom ved AJCC V7 -trin
- Trin IVA uterus corpus carcinoma eller carcinosarcoma af AJCC V7 -trin
- Trin IVB livmoderkorpuscarcinom eller carcinosarkom ved AJCC V7 -trin
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To estimate the hazard of progression or death of each of the three arms relative to that of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three arms.
III. To estimate the proportion of patients with measurable disease who have confirmed objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well as secondary measures of clinical outcome (overall survival, tumor response, or disease status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase (PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization (aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85013
- Saint Joseph's Hospital and Medical Center
-
Scottsdale, Arizona, Forenede Stater, 85259
- Mayo Clinic in Arizona
-
Tucson, Arizona, Forenede Stater, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank, California, Forenede Stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Concord, California, Forenede Stater, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Forenede Stater, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Forenede Stater, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Mountain View, California, Forenede Stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
San Diego, California, Forenede Stater, 92103
- UC San Diego Medical Center - Hillcrest
-
San Diego, California, Forenede Stater, 92161
- San Diego VA Medical Center
-
San Francisco, California, Forenede Stater, 94115
- UCSF Medical Center-Mount Zion
-
Walnut Creek, California, Forenede Stater, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- UCHealth University of Colorado Hospital
-
Englewood, Colorado, Forenede Stater, 80110
- Rocky Mountain Gynecologic Oncology PC
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
New Britain, Connecticut, Forenede Stater, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, Forenede Stater, 19958
- Beebe Medical Center
-
Newark, Delaware, Forenede Stater, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33756
- Morton Plant Hospital
-
Jacksonville, Florida, Forenede Stater, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Forenede Stater, 32806
- Orlando Health Cancer Institute
-
Orlando, Florida, Forenede Stater, 32803
- AdventHealth Orlando
-
-
Georgia
-
Macon, Georgia, Forenede Stater, 31201
- Central Georgia Gynecologic Oncology
-
Savannah, Georgia, Forenede Stater, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forenede Stater, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Forenede Stater, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Forenede Stater, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Forenede Stater, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Forenede Stater, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Forenede Stater, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, Forenede Stater, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
Wailuku, Hawaii, Forenede Stater, 96793
- Maui Memorial Medical Center
-
Wailuku, Hawaii, Forenede Stater, 96793
- Pacific Cancer Institute of Maui
-
‘Aiea, Hawaii, Forenede Stater, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Elgin, Illinois, Forenede Stater, 60123
- Advocate Sherman Hospital
-
Hinsdale, Illinois, Forenede Stater, 60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Hinsdale, Illinois, Forenede Stater, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
-
Indiana
-
Elkhart, Indiana, Forenede Stater, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Forenede Stater, 46514
- Michiana Hematology Oncology PC-Elkhart
-
Elkhart, Indiana, Forenede Stater, 46514-2098
- Elkhart Clinic
-
Indianapolis, Indiana, Forenede Stater, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Kokomo, Indiana, Forenede Stater, 46904
- Community Howard Regional Health
-
La Porte, Indiana, Forenede Stater, 46350
- IU Health La Porte Hospital
-
Mishawaka, Indiana, Forenede Stater, 46545
- Michiana Hematology Oncology PC-Mishawaka
-
Mishawaka, Indiana, Forenede Stater, 46545
- Saint Joseph Regional Medical Center-Mishawaka
-
Plymouth, Indiana, Forenede Stater, 46563
- Michiana Hematology Oncology PC-Plymouth
-
South Bend, Indiana, Forenede Stater, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Forenede Stater, 46628
- Northern Indiana Cancer Research Consortium
-
South Bend, Indiana, Forenede Stater, 46617
- South Bend Clinic
-
Westville, Indiana, Forenede Stater, 46391
- Michiana Hematology Oncology PC-Westville
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Forenede Stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Forenede Stater, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Forenede Stater, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Forenede Stater, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Forenede Stater, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Forenede Stater, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Cancer Center
-
Kingman, Kansas, Forenede Stater, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Forenede Stater, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Forenede Stater, 67905
- Cancer Center of Kansas-Liberal
-
McPherson, Kansas, Forenede Stater, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Forenede Stater, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Forenede Stater, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Forenede Stater, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Forenede Stater, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Forenede Stater, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Forenede Stater, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Forenede Stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forenede Stater, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Forenede Stater, 67208
- Associates In Womens Health
-
Wichita, Kansas, Forenede Stater, 67214
- Wichita NCI Community Oncology Research Program
-
Winfield, Kansas, Forenede Stater, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Forenede Stater, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Forenede Stater, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Maine
-
Portland, Maine, Forenede Stater, 04102
- MaineHealth Maine Medical Center - Portland
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Forenede Stater, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Forenede Stater, 21204
- Greater Baltimore Medical Center
-
Elkton, Maryland, Forenede Stater, 21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Springfield, Massachusetts, Forenede Stater, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, Forenede Stater, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Dearborn, Michigan, Forenede Stater, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Forenede Stater, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Forenede Stater, 48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint, Michigan, Forenede Stater, 48503
- Hurley Medical Center
-
Jackson, Michigan, Forenede Stater, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Niles, Michigan, Forenede Stater, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron, Michigan, Forenede Stater, 48060
- Lake Huron Medical Center
-
Royal Oak, Michigan, Forenede Stater, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Forenede Stater, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Warren, Michigan, Forenede Stater, 48093
- Henry Ford Health Warren Hospital
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Forenede Stater, 39216
- Saint Dominic-Jackson Memorial Hospital
-
Pascagoula, Mississippi, Forenede Stater, 39581
- Singing River Hospital
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla, Missouri, Forenede Stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Forenede Stater, 65804
- Cancer Research for the Ozarks NCORP
-
Springfield, Missouri, Forenede Stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63104
- SSM Health Saint Louis University Hospital
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- Women's Cancer Center of Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Forenede Stater, 89502
- Center of Hope at Renown Medical Center
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Cooper Hospital University Medical Center
-
Morristown, New Jersey, Forenede Stater, 07960
- Morristown Medical Center
-
Mount Holly, New Jersey, Forenede Stater, 08060
- Virtua Memorial
-
Newark, New Jersey, Forenede Stater, 07101
- Rutgers New Jersey Medical School
-
Phillipsburg, New Jersey, Forenede Stater, 08865
- Saint Luke's Hospital-Warren Campus
-
Summit, New Jersey, Forenede Stater, 07902
- Overlook Hospital
-
Voorhees Township, New Jersey, Forenede Stater, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Women's Cancer Care Associates LLC
-
Brightwaters, New York, Forenede Stater, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, Forenede Stater, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Fresh Meadows, New York, Forenede Stater, 11365
- New York Hospital Medical Center of Queens
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28816
- Hope Women's Cancer Centers-Asheville
-
Burlington, North Carolina, Forenede Stater, 27215
- Cone Health Cancer Center at Alamance Regional
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Forenede Stater, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System - Akron Campus
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forenede Stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forenede Stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, Forenede Stater, 45409
- Miami Valley Hospital
-
Kettering, Ohio, Forenede Stater, 45429
- Kettering Medical Center
-
Mayfield Heights, Ohio, Forenede Stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forenede Stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington, Pennsylvania, Forenede Stater, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Forenede Stater, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Pennsylvania Hospital
-
State College, Pennsylvania, Forenede Stater, 16801
- Geisinger Medical Group
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Forenede Stater, 29210
- South Carolina Oncology Associates PA
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Forenede Stater, 75390
- Clements University Hospital
-
Galveston, Texas, Forenede Stater, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, Forenede Stater, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Forenede Stater, 77030
- UT MD Anderson Cancer Center
-
Temple, Texas, Forenede Stater, 76508
- Scott and White Memorial Hospital
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia Cancer Center
-
Hampton, Virginia, Forenede Stater, 23666
- Virginia Oncology Associates-Hampton
-
Norfolk, Virginia, Forenede Stater, 23502
- Virginia Oncology Associates - Norfolk
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Forenede Stater, 24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Bellingham, Washington, Forenede Stater, 98226
- PeaceHealth Medical Group PC
-
Everett, Washington, Forenede Stater, 98201
- Providence Regional Cancer Partnership
-
Mount Vernon, Washington, Forenede Stater, 98274
- Skagit Regional Health Cancer Care Center
-
Poulsbo, Washington, Forenede Stater, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forenede Stater, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Forenede Stater, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Forenede Stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forenede Stater, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forenede Stater, 98133
- University of Washington Medical Center - Northwest
-
Sequim, Washington, Forenede Stater, 98384
- Olympic Medical Cancer Care Center
-
Silverdale, Washington, Forenede Stater, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Forenede Stater, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Forenede Stater, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma, Washington, Forenede Stater, 98405
- MultiCare Tacoma General Hospital
-
Tacoma, Washington, Forenede Stater, 98405
- Saint Joseph Medical Center
-
Walla Walla, Washington, Forenede Stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Wenatchee, Washington, Forenede Stater, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Wisconsin
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Aurora Sinai Medical Center
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
West Allis, Wisconsin, Forenede Stater, 53227
- Aurora West Allis Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma
-
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
-
Patients must not be eligible for a higher priority GOG protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population
-
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1
-
Platelets greater than or equal to 100,000/mcl
-
Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN), CTCAE v3.0 grade 1
-
Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)
-
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment)
-
UPC ratio of spot urine is an estimation of the 24 urine protein excretion
- A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
-
-
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN
-
Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)
-
Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)
-
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
-
Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway targeted therapy; patients must NOT have received prior therapy with temsirolimus, everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted therapy
-
Patients may have receive prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy; the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided on the Fast Fact Sheet (FFS) at registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
-
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
-
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
-
Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
-
Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to the first date of study therapy; patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected
-
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
-
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases
-
Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
- Myocardial infarction or unstable angina within 6 months of the first date of study therapy
- New York Heart Association (NYHA) class II or greater congestive heart failure
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study therapy.
- Aortic aneurysm and/or history of aortic dissection
-
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
-
Patients undergoing invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab or temsirolimus therapy
- Major surgical procedure anticipated during the course of the study.
- Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of study therapy
-
Patients with known prior history of interstitial pneumonitis
-
Patients with CTCAE v. 3, grade 2 or greater hypoxemia
-
Patients with CTCAE v. 3, grade 2 or greater dyspnea
-
Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin A1C (HgbA1C) > 8
-
Patients with peripheral neuropathy > CTCAE v.3, grade 1
-
Patients who are pregnant or nursing
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm I (paclitaxel, carboplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Given IV
Andre navne:
Correlative studies Given IV
Andre navne:
|
|
Eksperimentel: Arm II (paclitaxel, carboplatin, temsirolimus)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Given IV
Andre navne:
Correlative studies Given IV
Andre navne:
|
|
Eksperimentel: Arm III (ixabepilone, carboplatin, bevacizumab)
Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Correlative studies Given IV
Andre navne:
Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Who Progressed or Died by 25 Months From Enrollment
Tidsramme: at 25 months
|
PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574 |
at 25 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hyppighed og sværhedsgrad af toksicitet som vurderet af CTCAE v3.0 for hver af de tre arme.
Tidsramme: Median på 10 behandlingscyklusser plus 30 dage
|
Median på 10 behandlingscyklusser plus 30 dage
|
|
|
The Median Duration of Overall Survival for Each of the Three Arms.
Tidsramme: Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
|
The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
Tidsramme: Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required. |
Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Carol Aghajanian, NRG Oncology
Publikationer og nyttige links
Generelle publikationer
- Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3.
- Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113-121. doi: 10.1016/j.ygyno.2021.01.025. Epub 2021 Feb 2.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Koordinationskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Sundhedsøkonomi og organisationer
- Makrolider
- Lactoner
- Immunoglobulin -isotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Polyketider
- Økonomi
- Bevacizumab
- Sirolimus
- Carboplatin
- Paclitaxel
- Immunoglobulin G
- Epothilones
- Disulfider
- temsirolimus
- Ixabepilone
- Skatter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2011-01969
- U10CA180868 (U.S. NIH-bevilling/kontrakt)
- U10CA027469 (U.S. NIH-bevilling/kontrakt)
- NCI-2011-01969 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- GOG-0086P (Anden identifikator: CTEP)
- CDR0000654472
- GOG-0086P
- GOG-0086P (Anden identifikator: NRG Oncology)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .